Tumors induce de novo steroid biosynthesis in T cells to evade immunity

Bidesh Mahata, Jhuma Pramanik, Louise van der Weyden, Krzysztof Polański, Gozde Kar, Angela Riedel, Xi Chen, Nuno A. Fonseca, Kousik Kundu, Lia S. Campos, Edward J. Ryder, Graham Duddy, Izabela Walczak, Klaus Okkenhaug, David J. Adams, Jacqueline D. Shields, Sarah A. TeichmannbioRxiv 2018 · DOI

TL;DR

This paper reveals that tumors can hijack T cells, forcing them to produce steroids de novo (from scratch). This T cell-driven steroidogenesis creates an immunosuppressive tumor microenvironment, helping tumors evade the immune system. Importantly, blocking this pathway restores anti-tumor immunity, suggesting a new therapeutic target.

What Problem Does This Paper Address?

Cancer cells are masters of disguise, finding ways to hide from and disarm the immune system. While we know tumors can suppress immune responses, the precise mechanisms are still being uncovered. This paper dives into how tumors might manipulate immune cells themselves to create this immunosuppressive environment, specifically focusing on the role of steroid production within T cells. The authors investigate whether T cells, which are crucial for fighting cancer, can be reprogrammed by tumors to produce steroids, thereby dampening their own anti-tumor activity.

Methods

The researchers employed a multi-pronged approach:

  • Novel Transgenic Mouse Models: They engineered two key mouse lines:
  • A reporter mouse (Cyp11a1-mCherry) that lights up T cells producing steroids, allowing them to visualize and track these cells.
  • A conditional knockout mouse (Cyp11a1 cKO) where they could specifically disable the steroid-producing gene (Cyp11a1) in T cells.
  • Flow Cytometry: Used extensively to identify and quantify different immune cell populations and their steroidogenic activity (e.g., measuring mCherry expression).
  • Genetic Manipulation: Created conditional knockout mice to specifically ablate the Cyp11a1 gene in T cells.
  • Pharmacological Inhibition: Used aminoglutethimide (AG), a drug that inhibits steroidogenesis, to block the pathway.
  • Tumor Models: Utilized established B16-F10 melanoma and EO771 breast cancer models in mice to study tumor growth and metastasis.
  • Transcriptomic Analysis: Examined gene expression (mRNA) in tumor-infiltrating immune cells to understand the molecular changes associated with steroidogenesis and immune responses.
  • ELISA: Measured steroid levels (pregnenolone) in tumor samples.

Datasets

The study primarily utilized data generated from their own experiments using the developed mouse models and tumor models. They also analyzed publicly available transcriptomic data sets of human tumors to confirm the relevance of their findings in a human context.

Key Insights and Ideas

  • T Cells as Steroid Factories: The most striking finding is that T cells, particularly CD4+ T helper cells, can be induced by tumors to perform de novo steroidogenesis. This is a significant departure from the traditional understanding of steroid production being limited to specialized endocrine glands.
  • Tumor-Induced Reprogramming: Tumors actively induce this steroidogenic capacity in T cells within the tumor microenvironment (TME), suggesting a direct manipulation of immune cells for immune evasion.
  • Steroids as Immuno-suppressors: The steroids produced by these reprogrammed T cells act as immunosuppressants, dampening the anti-tumor immune response.
  • Targeting Steroidogenesis Restores Immunity: Inhibiting this T cell steroidogenesis pathway, either genetically or pharmacologically, significantly boosts anti-tumor immunity.

Key Results

  • Identification of Steroidogenic T cells: The reporter mice clearly showed Cyp11a1 expression (indicating steroidogenesis) in T cells within established tumors, but not in healthy tissues or draining lymph nodes.
  • Tumor Growth Inhibition: Genetic ablation of Cyp11a1 in T cells significantly restricted primary tumor growth and lung metastasis in mouse models.
  • Pregnenolone Restoration: Supplementing with pregnenolone (a key steroid precursor) could partially rescue tumor growth in Cyp11a1-deficient T cells, confirming the role of steroid synthesis.
  • Immune Cell Rebalancing: Inhibiting T cell steroidogenesis shifted the immune landscape within the tumor, increasing pro-inflammatory M1 macrophages and cytotoxic T cells, while decreasing immunosuppressive M2 macrophages and regulatory T cells.
  • Enhanced Cytotoxic Function: T cells from Cyp11a1-deficient mice showed enhanced degranulation, a marker of cytotoxic activity.
  • Human Relevance: Steroidogenic gene expression was found to be correlated with IL-4 expression in human melanoma samples, supporting the relevance of these findings in human cancer.

Limitations and Future Work

  • Specific Steroid Effects: While the study demonstrates T cell steroidogenesis and its immunosuppressive effects, the specific roles of individual steroids produced by these T cells (beyond pregnenolone's role in rescue experiments) and their precise downstream targets within the TME require further investigation.
  • Context Dependency: The authors acknowledge that the specific immune cell types involved in steroidogenesis might vary depending on the tumor type and the broader immunologic context. Future studies could explore this in more diverse cancer models.
  • Therapeutic Translation: While promising, translating these findings into clinical therapies will require further research into the optimal drug targets, delivery methods, and potential side effects of inhibiting T cell steroidogenesis in cancer patients. The authors suggest that stratifying patients based on steroidogenic gene expression or using anti-steroidogenic drugs could be future therapeutic strategies.

Summary updated

Abstract

ABSTRACT Tumors subvert immune cell function to evade immune responses, yet the complex mechanisms driving immune evasion remain poorly understood. Here we show that tumors induce de novo steroidogenesis in T lymphocytes to evade anti-tumor immunity. Using a novel transgenic steroidogenesis-reporter mouse line we identify and characterize de novo steroidogenic immune cells. Genetic ablation of T cell steroidogenesis restricts primary tumor growth and metastatic dissemination in mouse models. Steroidogenic T cells dysregulate anti-tumor immunity, and inhibition of the steroidogenesis pathway was sufficient to restore anti-tumor immunity. This study demonstrates T cell de novo steroidogenesis as a mechanism of anti-tumor immunosuppression and a potential druggable target.
BibTeX
@misc{mahata2018tumors,
  author = {Bidesh Mahata and Jhuma Pramanik and Louise van der Weyden and Krzysztof Polański and Gozde Kar and Angela Riedel and Xi Chen and Nuno A. Fonseca and Kousik Kundu and Lia S. Campos and Edward J. Ryder and Graham Duddy and Izabela Walczak and Klaus Okkenhaug and David J. Adams and Jacqueline D. Shields and Sarah A. Teichmann},
  title = {{Tumors induce <i>de novo</i> steroid biosynthesis in T cells to evade immunity}},
  year = {2018},
  doi = {10.1101/471359},
  howpublished = {bioRxiv},
}
Figure